研发管线

发表文献

临床产品线

临床前产品线

肿瘤靶向的双特异性CD28 POWERbodyTM强力抗体

Tumor-targeted CD28 bispecific POWERbodyTM for safe and synergistic T cell-mediated immunotherapy
CD28 bispecific POWERbody | AACR 2022